Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (145) 145
index medicus (116) 116
male (113) 113
female (106) 106
middle aged (100) 100
adult (75) 75
life sciences (61) 61
aged (57) 57
gastroenterology & hepatology (56) 56
hepatitis c virus (45) 45
treatment outcome (42) 42
gastroenterology and hepatology (40) 40
antiviral agents - therapeutic use (39) 39
hepatitis c (38) 38
infection (36) 36
therapy (36) 36
cirrhosis (34) 34
infectious diseases (34) 34
hepatitis (33) 33
immunology (33) 33
ribavirin (32) 32
health aspects (30) 30
hepacivirus - genetics (29) 29
surgery (28) 28
france (26) 26
liver (26) 26
virology (26) 26
abridged index medicus (25) 25
hepatitis c, chronic - drug therapy (25) 25
human health and pathology (25) 25
prospective studies (25) 25
patients (24) 24
risk factors (24) 24
virus diseases (24) 24
analysis (23) 23
interferon (23) 23
genotype (22) 22
transplantation (22) 22
care and treatment (20) 20
drug therapy, combination (19) 19
hepatitis c - complications (19) 19
interferon-alpha - therapeutic use (19) 19
viruses (19) 19
digestive system diseases (18) 18
infections (18) 18
ribavirin - therapeutic use (18) 18
time factors (18) 18
antiviral agents (17) 17
cancer (17) 17
hepatitis c - drug therapy (17) 17
liver cirrhosis (17) 17
risk (17) 17
sofosbuvir (16) 16
[sdv]life sciences [q-bio] (15) 15
antiviral agents - adverse effects (15) 15
hepatitis c, chronic - virology (15) 15
hepatitis e virus (15) 15
hépatology and gastroenterology (15) 15
microbiology (15) 15
mortality (15) 15
pharmacology & pharmacy (15) 15
[ sdv ] life sciences [q-bio] (14) 14
aged, 80 and over (14) 14
animals (14) 14
france - epidemiology (14) 14
retrospective studies (14) 14
sustained virological response (14) 14
antiviral agents - administration & dosage (13) 13
chronic hepatitis-c (13) 13
diagnosis (13) 13
drug therapy (13) 13
genotypes (13) 13
hepatitis c - virology (13) 13
kidney transplantation (13) 13
liver cirrhosis - virology (13) 13
management (13) 13
medicine (13) 13
plus ribavirin (13) 13
virus-infection (13) 13
hcv (12) 12
hepatitis b (12) 12
hepatitis e (12) 12
medical research (12) 12
polyethylene glycols - therapeutic use (12) 12
recombinant proteins (12) 12
viral load (12) 12
young adult (12) 12
[sdv.mhep.heg]life sciences [q-bio]/human health and pathology/hépatology and gastroenterology (11) 11
cohort studies (11) 11
disease (11) 11
epidemiology (11) 11
hepatitis-c virus (11) 11
hiv (11) 11
liver cancer (11) 11
liver transplantation (11) 11
medicine, experimental (11) 11
multivariate analysis (11) 11
recipients (11) 11
research (11) 11
ribavirin - administration & dosage (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
by Charlier, Caroline, Dr and Perrodeau, Élodie, MSc and Leclercq, Alexandre, MSc and Cazenave, Benoît, MD and Pilmis, Benoît, MD and Henry, Benoît, MD and Lopes, Amanda, MD and Maury, Mylène M, PhD and Moura, Alexandra, PhD and Goffinet, François, MD and Dieye, Hélène Bracq and Thouvenot, Pierre and Ungeheuer, Marie-Noëlle, MD and Tourdjman, Mathieu, MD and Goulet, Véronique, MD and de Valk, Henriette, MD and Lortholary, Olivier, Prof and Ravaud, Philippe, Prof and Lecuit, Marc, Prof and MONALISA Study Grp and MONALISA study group
Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
by Lawitz, Eric, Prof and Gane, Edward, Prof and Pearlman, Brian, Prof and Tam, Edward, MD and Ghesquiere, Wayne, Prof and Guyader, Dominique, Prof and Alric, Laurent, MD and Bronowicki, Jean-Pierre, Prof and Lester, Laura, MSN and Sievert, William, Prof and Ghalib, Reem, MD and Balart, Luis, MD and Sund, Fredrik, MD and Lagging, Martin, Prof and Dutko, Frank, PhD and Shaughnessy, Melissa, MS and Hwang, Peggy, PhD and Howe, Anita Y M, PhD and Wahl, Janice, MD and Robertson, Michael, MD and Barr, Eliav, MD and Haber, Barbara, MD and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Infektionssjukdomar and Uppsala universitet and Institutionen för medicinska vetenskaper
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1075 - 1086
Summary Background There is a high medical need for an interferon-free, all-oral, short-duration therapy for hepatitis C virus (HCV) that is highly effective... 
Internal Medicine | SUSTAINED VIROLOGICAL RESPONSE | MEDICINE, GENERAL & INTERNAL | PLUS RIBAVIRIN | HCV NS5A INHIBITOR | SOFOSBUVIR | TREATMENT-EXPERIENCED PATIENTS | DISEASE BURDEN | DOUBLE-BLIND | SIMEPREVIR | INTERFERON-ALPHA 2A | TREATMENT-NAIVE PATIENTS | Humans | Middle Aged | Hepacivirus - genetics | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Male | RNA, Viral - blood | Interferons - therapeutic use | Hepatitis C, Chronic - complications | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Ribavirin - administration & dosage | Treatment Failure | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Liver Cirrhosis - etiology | Drug Administration Schedule | Quinoxalines - administration & dosage | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Adolescent | Aged | Medical colleges | Protease inhibitors | Proteases | Clinical trials | Product development | Biological response modifiers | Hepatitis C virus | Health aspects | Liver cirrhosis | Ribavirin | Comparative studies | Hepatitis | Genotype & phenotype | Interferon | Drug therapy | Life Sciences | Infectious Medicine | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Infektionsmedicin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
by Bourlière, Marc, Dr and Bronowicki, Jean-Pierre, MD and de Ledinghen, Victor, MD and Hézode, Christophe, MD and Zoulim, Fabien, MD and Mathurin, Philippe, MD and Tran, Albert, MD and Larrey, Dominique G, MD and Ratziu, Vlad, MD and Alric, Laurent, MD and Hyland, Robert H, DPhil and Jiang, Deyuan, PhD and Doehle, Brian, PhD and Pang, Phillip S, MD and Symonds, William T, PharmD and Subramanian, G Mani, MD and McHutchison, John G, MD and Marcellin, Patrick, MD and Habersetzer, François, MD and Guyader, Dominique, MD and Grangé, Jean-Didier, MD and Loustaud-Ratti, Véronique, MD and Serfaty, Lawrence, MD and Metivier, Sophie, MD and Leroy, Vincent, MD and Abergel, Armand, MD and Pol, Stanislas, MD
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 4, pp. 397 - 404
Summary Background Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection are at risk of life-threatening complications, but... 
Infectious Disease | SUSTAINED VIROLOGICAL RESPONSE | FIBROSIS | INFECTIOUS DISEASES | TREATMENT-NAIVE | TELAPREVIR | HEPATITIS-C VIRUS | PLUS SOFOSBUVIR | ACCESS PROGRAM | TREATMENT-EXPERIENCED PATIENTS | PEGYLATED INTERFERON | BOCEPREVIR | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Young Adult | Adult | Female | France | Placebos - administration & dosage | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Liver Cirrhosis - virology | Uridine Monophosphate - analogs & derivatives | Adolescent | Aged | Hepacivirus - classification | Care and treatment | Proteases | Clinical trials | Product development | Genetic aspects | Hepatitis C virus | Hepatitis C | Health aspects | Liver cirrhosis | Ribavirin | Genotype & phenotype | Liver cancer | Interferon | Mortality | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Chronic hepatitis E virus infection: Successful virologic response to pegylated interferon-α therapy
by Alric, Laurent and Bonnet, Delphine and Laurent, Guy and Kamar, Nassim and Izopet, Jacques
Annals of Internal Medicine, ISSN 0003-4819, 07/2010, Volume 153, Issue 2, pp. 135 - 136
MEDICINE, GENERAL & INTERNAL | Hepatitis E - drug therapy | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepatitis E - immunology | Interferon-alpha - therapeutic use | Male | Immunocompromised Host | Chronic Disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Thermodynamic stability and kinetic inertness of a Gd-DTPA bisamide complex grafted onto gold nanoparticles
by Mogilireddy, Vijetha and Déchamps-Olivier, Isabelle and Alric, Christophe and Laurent, Gautier and Laurent, Sophie and Vander Elst, Luce and Muller, Robert and Bazzi, Rana and Roux, Stéphane and Tillement, Olivier and Chuburu, Françoise
Contrast Media and Molecular Imaging, ISSN 1555-4309, 05/2015, Volume 10, Issue 3, pp. 179 - 187
Gold nanoparticles coated by gadolinium (III) chelates (Au@DTDTPA) where DTDTPA is a dithiolated bisamide derivative of... 
Nanoparticles | Thermodynamics | Imaging agents | Gadolinium chelates | Kinetics | nanoparticles | CONSTANTS | gadolinium chelates | TRANSMETALATION | EQUILIBRIUM | thermodynamics | imaging agents | MODEL | kinetics | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | RESONANCE CONTRAST AGENTS | Gold - chemistry | Metal Nanoparticles - chemistry | Magnetic Resonance Imaging - methods | Tomography, X-Ray Computed - methods | Contrast Media - chemistry | Chelating Agents | Gadolinium - chemistry | Gadolinium DTPA - chemistry
Journal Article
Details down arrow
6. Full Text The In Vivo Radiosensitizing Effect of Gold Nanoparticles Based MRI Contrast Agents
by Miladi, Imen and Alric, Christophe and Dufort, Sandrine and Mowat, Pierre and Dutour, Aurélie and Mandon, Céline and Laurent, Gautier and Bräuer‐Krisch, Elke and Herath, Nirmitha and Coll, Jean‐Luc and Dutreix, Marie and Lux, François and Bazzi, Rana and Billotey, Claire and Janier, Marc and Perriat, Pascal and Le Duc, Géraldine and Roux, Stéphane and Tillement, Olivier
Small, ISSN 1613-6810, 03/2014, Volume 10, Issue 6, pp. 1116 - 1124
The gadolinium chelate coated gold nanoparticles (Au@DTDTPA‐Gd 50 ) which were designed as contrast agents for magnetic resonance imaging (MRI) also behave as... 
nanomedicine | magnetic resonance imaging | gold nanoparticles | radiosensitization | CELLS | PHYSICS, CONDENSED MATTER | PHYSICS, APPLIED | PARTICLES | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | BIODISTRIBUTION | TUMORS | CHEMISTRY, MULTIDISCIPLINARY | CANCER-THERAPY | MICROBEAM RADIATION-THERAPY | ENHANCEMENT | X-RAY-BEAMS | MICE | RADIOTHERAPY | Gold | Cell Survival | Humans | Rats | Spleen - cytology | Osteosarcoma - diagnosis | Radiation-Sensitizing Agents | Rats, Sprague-Dawley | Magnetic Resonance Imaging | Animals | Contrast Media | Survival Analysis | Brain - pathology | Cell Line, Tumor | Osteosarcoma - pathology | Metal Nanoparticles | Nanoparticles | Magnetic resonance imaging | Radiotherapy | Chelates | Nuclear magnetic resonance--NMR | Radiation therapy | Contrast agents | Irradiation | Position (location) | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pretreatment with standard‐dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP)
by Essilini, Anaïs and Comont, Thibault and Germain, Johanne and Brun, Natacha and Dingremont, Claire and Castel, Brice and Arista, Sophie and Madaule, Serge and Sailler, Laurent and Lapeyre‐Mestre, Maryse and Beyne‐Rauzy, Odile and Godeau, Bertrand and Adoue, Daniel and Moulis, Guillaume and Alric, Laurent and Balardy, Laurent and Betrian, Sarah and Borel, Cécile and Bonnet, Delphine and Brechemier, Delphine and Carreiro, Miguel and Cougoul, Pierre and Danu, Alina and Delavigne, Karen and Faurie, Thomas and Gaches, Francis and Gaspard, Marie‐Hélène and Godel‐Labouret, Aurélie and Gaudin, Clément and Giraud, Patrick and Hadj‐Khelifa, Sondess and Hebraud, Benjamin and Khatibi, Sarah and Leplay, Lorraine and Leveneur, Yann and Ollier, Sylvie and Martel, Clothilde and Martin‐Blondel, Guillaume and Michaud, Martin and Roque, Philippe and Nuccio, Fanny and Prudhomme, Laurent and Pugnet, Grégory and Recher, Christian and Remy, Véronique and Sire, Stéphane and Sommet, Agnès and Tavitian, Suzanne and Vaillant, Willy and CARMEN Investigators Grp and the CARMEN investigators group
European Journal of Haematology, ISSN 0902-4441, 05/2018, Volume 100, Issue 5, pp. 412 - 418
Objective: To assess the benefits and harms to initiate corticosteroids with intravenous methylprednisolone at a conventional dose (1 mg/kg/d) to treat adults... 
methylprednisolone | thrombocytopenic | corticosteroids | prednisone | idiopathic | purpura | TRIAL | ADULTS | HEMATOLOGY | CARMEN | EPIDEMIOLOGY | Thrombocytopenia | Corticosteroids | Methylprednisolone | Patient outcomes | Standards | Corticoids | Prednisone | Intravenous administration | Response rates
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights